ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 1075 • ACR Convergence 2022

    Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype

    Benjamin Terrier1, David Jayne2, Bernhard Hellmich3, Jane Bentley4, Jonathan Steinfeld5, Steven Yancey6, Namhee Kwon7, Praveen Akuthota8, Paneez Khoury9, Lee Baylis10 and Michael Wechsler11, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2University of Cambridge, Cambridge, United Kingdom, 3Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 4Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, 5Clinical Sciences, Respiratory, GSK (affiliation at time of research), Philadelphia, PA, 6Respiratory Therapeutic Area, GSK (affiliation at the time of research), Research Triangle Park, NC, 7Clinical Sciences, Respiratory, GSK, Brentford, United Kingdom, 8Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California, San Diego, CA, 9Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 10Global Medical Affairs, GlaxoSmithKline, Durham, NC, 11Department of Medicine, National Jewish Health, Denver, CO

    Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) can have vasculitic or eosinophilic phenotypes. The MIRRA study demonstrated that patients with EGPA spent more time…
  • Abstract Number: 1551 • ACR Convergence 2022

    The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

    Saja Almaaitah1, Chao Zhang2 and alexandra villa forte1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Takayasu Arteritis (TA) is a complex large vessel vasculitis that leads to arterial stenosis, occlusion and aneurysmal formation. Assessment of disease activity is a…
  • Abstract Number: 1575 • ACR Convergence 2022

    Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Larson4, Cristina Burroughs5 and Peter Merkel6, 1Vanderbilt University Medical Center, Nashville, TN, 2University of California Los Angeles, Los Angeles, CA, 3Vasculitis Foundation, Chapel Hill, NC, 4Vasculitis Foundation, Kansas City, MO, 5University of South Florida, Tampa, FL, 6University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
  • Abstract Number: 2232 • ACR Convergence 2022

    Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients

    Julien ROHMER1, ludovic trefond2, Yann Nguyen3, Christian Agard4, Jean Sebastien ALLAIN5, Alice Berezne6, Pierre Charles7, Pascal Cohen8, guillaume gondran9, Matthieu GROH10, Tessa HUSCENOT11, carole lacout12, Estibaliz Lazaro13, Jonathan London14, Francois Maurier15, Arsene Mekinian16, Isabelle Nubourgh17, Rafik MESBAH18, Xavier Puéchal8, Laurent Perard19, Mathieu Puyade20, Gregory Pugnet21, Viviane Queyrel22, Diane Rouzaud23, Arthur Roux24, Cecile-Audrey DUREL19, Loïc Guillevin8 and Benjamin Terrier8, 1APHP, Suresnes, France, 2Chu clermont ferrand, Clermont-Ferrand, France, 3AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5CHU rennes, Rennes, 6CH Annecy, Annecy, France, 7Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 9CHU limoges, Limoges, France, 10Foch Hospital, Suresnes, France, 11APHP, Boulogne, France, 12CHU Angers, Angers, France, 13Bordeaux Hospital University, Bordeaux, France, 14Hôpital Croix-Saint-Simon, Paris, France, 15Hôpitaux privés de Metz, Metz, France, 16AP-HP, Hopital Saint Antoine, Paris, France, 17Ch St Pierre, Brussels, Belgium, 18Boulogne Ch, Boulogne, France, 19CHU Lyon, Lyon, France, 20Centre Hospitalier Universitaire de Poitiers, Poitiers, France, 21CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, 22CHU NIce, Nice, France, 23Bichat, Paris, France, 24MGEN, Paris, France

    Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
  • Abstract Number: 0038 • ACR Convergence 2022

    STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)

    Sachin Gaurav1, Bin Lin2, Sophia Park3, Shankar Venkatraman4, David Winkler4 and Raphaela Goldbach-Mansky5, 1Translational Autoinflammatory Diseases Section, LCIM, NIAID,, Bethesda, MD, 2NIH, Bethesda, MD, 3NIAID, Bethesda, MD, 4IFM Therapeutics, Boston, MA, 5NIH/NIAID, Potomac, MD

    Background/Purpose: SAVI is a rare, autoinflammatory type I interferonopathy caused by gain-of-function mutations that cause STING activation and excessive production of type I interferons and…
  • Abstract Number: 0463 • ACR Convergence 2022

    Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center

    Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive…
  • Abstract Number: 0488 • ACR Convergence 2022

    Discrepancies in Temporal Artery Biopsy Positivity Rate Among White and Black Patients Suspected of Having Giant Cell Arteritis: Experience from a Tertiary Academic Medical Center

    Raj Vachhani1, Peng Li2, Mehdi Tavakoli2, Lanning Kline2 and Angelo Gaffo2, 1University of Alabama at Birmingham, Homewood, AL, 2University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: A prior study evaluated incidence rates of biopsy proven giant cell arteritis (GCA) among black and white patients, concluding that GCA occurs at a…
  • Abstract Number: 1076 • ACR Convergence 2022

    ANCA-Associated Vasculitis Treated with Avacopan versus a Standard Prednisone Taper: Glucocorticoid Toxicity Index Scores by Domain

    Naomi Patel1, David Jayne2, Peter Merkel3, Pirow Bekker4, yuqing zhang5, Huibin Yue4 and John Stone6, 1Massachusetts General Hospital, Sale Creek, TN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4ChemoCentryx, San Juan Capistrano, CA, 5Massachusetts General Hospital, Quincy, MA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: The ADVOCATE trial (Jayne DRW et al, N Engl J Med, 2021) was a randomized, double-blind, controlled trial of avacopan vs prednisone in addition…
  • Abstract Number: 1552 • ACR Convergence 2022

    Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

    Hugh Alessi1, Yiming Luo1, Kaitlin Quinn2 and Peter Grayson3, 1NIH, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: A set of genes has been associated with aortopathies, which are defined as non-inflammatory diseases where the integrity of large arteries is compromised leading…
  • Abstract Number: 1576 • ACR Convergence 2022

    Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

    Umar Ghaffar1, Hannah Langenfeld2, Cynthia Crowson3, Tanaz Kermani4, Michelle Burke1, Boyd Viers1, Aaron Potretzke1, Haraldur Bjarnason1, Kenneth J. Warrington1 and Matthew J. Koster1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4University of California Los Angeles, West Hills, CA

    Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…
  • Abstract Number: 0044 • ACR Convergence 2022

    Follistatin-like Protein 1 Alters T Cell Receptor Signaling Dynamics in Vitro, While Expression in Vivo Correlates with Disease and Deficiency Increases Acute Inflammation in a Mouse Model of Kawasaki Disease

    Mateo Amezcua1, Janice Huang1, Miao Chen1, Renee Escalona2, Edward Dick2 and Mark Gorelik1, 1Columbia University, New York, NY, 2Texas Biomedical Research Institute, San Antonio, TX

    Background/Purpose: Kawasaki disease (KD) is an acute, febrile illness of childhood, associated with cardiac inflammation and vasculitis of coronary arteries and sometimes other medium sized…
  • Abstract Number: 0464 • ACR Convergence 2022

    JAKINIB in Refractory Giant Cell Arteritis. National Multicenter Study of 15 Cases and Literature Review

    Diana Prieto-Peña1, Javier Loricera2, Susana Romero Yuste3, Anne Riveros-Frutos4, F. Javier Narváez5, Eugenio De Miguel6, Valentina Emperiale7, Elena Becerra-Fernández8, Santos Castañeda9, Eztizen Labrador10, Olga Maiz11, Miguel Ángel González-Gay12 and Ricardo Blanco2, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Complexo Hospitalario Universitario, Pontevedra, Spain, 4Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 5Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario La Paz, Madrid, Spain, 7Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, 8Hospital Universitario de Torrevieja, London, United Kingdom, 9Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 10Hospital San Pedro, Logroño, Spain, 11Hospital Universitario de Donostia, San Sebastián, Spain, 12Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Giant Cell Arteritis (GCA) may be refractory to standard treatment with glucocorticoids and conventional and/or biologic disease-modifying antirheumatic drugs (cDMARDs/bDMARDs). The JAK/STAT signaling pathway…
  • Abstract Number: 0489 • ACR Convergence 2022

    Giant Cell Arteritis Phenotypes and Diagnosis of Aortitis Among 1852 Patients Before and After 2016 Across 10 French Referral Centers

    Laurent Sailler1, Kim Ly2, Hubert De Boysson3, Brigitte Granel4, Maxima Samson5, Christian Agard6, Laurence Bouillet7, Magnan Julie8, Marc Lambert9, Arsene Mekinian10, Lea Tarallo1, Eric Liozon2, Gregory Pugnet11, Jean Luc Davignon1, Achille Aouba12, Aurélie Daumas4, Quentin Gomes de Pinho4, bernard bonnotte13, simon parreau2, Samuel Deshayes12 and GEFA Collaborative group14, 1CHU Toulouse, Toulouse, France, 2CHU Limoges, Limoges, France, 3Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, 4AP-HM, Marseille, France, 5Dijon University Hospital, Dijon, France, 6Internal medicine, Nantes University Hospital, Nantes, France, 7Grenoble University Hospital, Grenoble, France, 8CHU Tours, Tours, France, 9CHU Lille, Lille, France, 10AP-HP, Hopital Saint Antoine, Paris, France, 11CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, 12CHU Caen, Caen, France, 13Centre Hospitalo-Universitaire de Dijon, Dijon, France, 14Saint Joseph Hospital, Marseille, France

    Background/Purpose: In 2016, French Internal medicine physicians collaborating in the Groupe d'Etude Français de l'Arterite à cellules géantes (GEFA) created a common database to build…
  • Abstract Number: 1080 • ACR Convergence 2022

    Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…
  • Abstract Number: 1555 • ACR Convergence 2022

    Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study

    Luigi Boiardi1, PIERLUIGI MACCHIONI2, Francesco Muratore1, GIULIA KLINOWSKI3, ELENA GALLI1, FEDERICA MACALUSO3, MASSIMILIANO CASALI1, GIULIA BESUTTI1 and Carlo Salvarani4, 1Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, 2IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 3IRCCS REGGIO EMILIA, Reggio Emilia, Italy, 4Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy

    Background/Purpose: Few studies compared the demographic, clinical, laboratory and imaging features, and outcomes of Takayasu arteritis (TAK) and large-vessel giant cell arteritis (LV-GCA). Aim of…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology